Invention Grant
- Patent Title: TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies
-
Application No.: US15300294Application Date: 2015-04-24
-
Publication No.: US10280208B2Publication Date: 2019-05-07
- Inventor: Xingxing Zang , Jordan M. Chinai , Murali Janakiram , Steven C. Almo , Andras Fiser
- Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
- Applicant Address: US NY Bronx
- Assignee: Albert Einstein College of Medicine
- Current Assignee: Albert Einstein College of Medicine
- Current Assignee Address: US NY Bronx
- Agency: Amster, Rothstein & Ebenstein LLP
- International Application: PCT/US2015/027429 WO 20150424
- International Announcement: WO2015/167948 WO 20151105
- Main IPC: C07K14/70
- IPC: C07K14/70 ; C07K14/705 ; A61K38/00
Abstract:
Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
Public/Granted literature
- US20170174742A1 TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES Public/Granted day:2017-06-22
Information query
